BCL2 and hepatocellular carcinoma: Consistent with the above results, both shRNAs-Gli2 and Hh inhibitors (cyclopamine/GANT61) decreased the protein levels of Gli2 and KIF20A, as well as Bcl2 (as a positive control) [17], in HCC-LM3 and MHCC-97H cells (Figure 1D and Supplementary Figure S1G).